The association between multiple sclerosis and pain medications.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
31
10
2018
medline:
27
6
2019
entrez:
31
10
2018
Statut:
ppublish
Résumé
The patients with multiple sclerosis (MS) are at greater risk of pain than people without the disease; however, the occurrence and characteristics of pain among these patients are incompletely described. We aimed to assess characteristics of pain amongst MS patients using MS patients who were recruited to participate in 3 studies in Sweden (n = 3877) and were matched with individuals without MS (n = 4548) by sex, year of birth, and region of residence. The Prescribed Drugs Register identified prescribed pain medication, overall and restricted to those given 4 or more prescriptions in 1 year to assess chronic pain. Anatomical therapeutic chemical codes classified whether pain was neuropathic, musculoskeletal, or migraine. Cox-proportional hazard models were used to estimate associations. Our findings showed the patients with MS were at increased risk of pain treatment, with a hazard ratio (HR) of 2.52 (95% confidence interval 2.38-2.66). The largest magnitude HR was for neuropathic pain (5.73, 5.07-6.47) for which 34.2% (n = 1326) of the MS and 7.15% (n = 325) of the non-MS cohort were prescribed a treatment. The HR for chronic pain treatment was 3.55 (3.27-3.84), indicating an increased effect size relative to any pain treatment. Chronic neuropathic pain showed the largest HR at 7.43 (6.21-8.89). Neuropathic pain was shown to be the primary mechanism leading to increased risk of pain in patients with MS.
Identifiants
pubmed: 30376533
doi: 10.1097/j.pain.0000000000001429
pii: 00006396-201902000-00016
doi:
Substances chimiques
Analgesics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
424-432Commentaires et corrections
Type : ErratumIn
Références
Altman DG, Bland JM. Uncertainty and sampling error. BMJ 2014;349:g7064.
Altman DG, Bland JM. Uncertainty beyond sampling error. BMJ 2014;349:g7065.
Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984;41:1270–2.
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009;32:1–32.
Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524–34.
Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006;12:629–38.
Elliott DG. Migraine in multiple sclerosis. Int Rev Neurobiol 2007;79:281–302.
Elrington G. Migraine: diagnosis and management. J Neurol Neurosurg Psychiatry 2002;72(suppl 2):ii10–ii15.
Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788–94.
Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology 2014;22:1–22.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–86.
Marrie RA. Psychiatric comorbidity in multiple sclerosis: it's not the genes. Mult Scler 2014;20:1803–5.
Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler 2015;21:342–9.
Milinis K, Tennant A, Young CA; Group TOs. Spasticity in multiple sclerosis: associations with impairments and overall quality of life. Mult Scler Relat Disord 2016;5:34–9.
Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. PAIN 2013;154:2691–9.
Morgan MM, Christie MJ. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 2011;164:1322–34.
O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. PAIN 2008;137:96–111.
Okuda DT, Melmed K, Matsuwaki T, Blomqvist A, Craig AD. Central neuropathic pain in MS is due to distinct thoracic spinal cord lesions. Ann Clin Transl Neurol 2014;1:554–61.
Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis—prevalence and clinical characteristics. Eur J Pain 2005;9:531–42.
Patejdl R, Zettl UK. Spasticity in multiple sclerosis: contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. Autoimmun Rev 2017;16:925–36.
Paul SL, Dewey HM, Sturm JW, Macdonell RA, Thrift AG. Prevalence of depression and use of antidepressant medication at 5-years poststroke in the North East Melbourne stroke incidence study. Stroke 2006;37:2854–5.
Persson A. Epidemiological investigation of multiple sclerosis—EIMS, 2016. Available at: https://ki.se/en/imm/epidemiological-investigation-of-multiple-sclerosis-eims.
Persson A. Genes and environment in multiple sclerosis—GEMS, 2016. Available at: https://ki.se/en/imm/genes-and-environment-in-multiple-sclerosis-gems.
Persson A. Immunomodulation and multiple sclerosis epidemiology study—IMSE, 2016. Available at: https://ki.se/en/imm/immunomodulation-and-multiple-sclerosis-epidemiology-study-imse.
Pottegard A, Hallas J. Assigning exposure duration to single prescriptions by use of the waiting time distribution. Pharmacoepidemiol Drug Saf 2013;22:803–9.
Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull 2010;95:79–104.
Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep 2013;13:320.
Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci 1995;16:629–32.
Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. PAIN 2005;114:473–81.
Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003;60:1089–94.
Tabby D, Majeed MH, Youngman B, Wilcox J. Headache in multiple sclerosis: features and implications for disease management. Int J MS Care 2013;15:73–80.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630–5.
Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260:351–67.
Wright LJ. Identifying and treating pain caused by MS. J Clin Psychiatry 2012;73:e23.